Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | GLS | O94925 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | EEF2K | O00418 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | FBP1 | P09467 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3901356 | 0.86 | ALDH1A1 (0.48) | ALDH1A1MAPTTSHRGLSLMNA | |
| SCHEMBL1743688 | 0.84 | ALDH1A1 (0.43) | ALDH1A1MAPTTSHRLMNASMN1; SMN2 | |
| SCHEMBL3901618 | 0.81 | ALDH1A1 (0.30) | ALDH1A1MAPTGLSSMN1; SMN2 | |
| SCHEMBL2773847 | 0.81 | SMN1; SMN2 (0.41) | ALDH1A1L3MBTL1LMNASMN1; SMN2NPC1 | |
| SCHEMBL3905827 | 0.80 | — | — | |
| SCHEMBL3905814 | 0.79 | NPC1 (0.30) | ALDH1A1L3MBTL1SMN1; SMN2FBP1NPC1 | |
| Hydrochloric Acid SCHEMBL2968730 | 0.79 | RAB9A (0.40) | ALDH1A1L3MBTL1LMNASMN1; SMN2NPC1 | |
| SCHEMBL3900149 | 0.78 | ALDH1A1 (0.36) | ALDH1A1MAPTTSHRGLSSMN1; SMN2 | |
| SCHEMBL3909193 | 0.76 | KDM4E (0.50) | ALDH1A1MAPTLMNASMN1; SMN2NPC1 | |
| SCHEMBL3902138 | 0.74 | NPC1 (0.30) | ALDH1A1L3MBTL1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8889670-B2 | Heterocyclic compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-18 | — | — | US | disclosed |
| US-20110312944-A1 | Heterocyclic Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312944-A1 | Heterocyclic Compounds Which Modulate The CB2 Receptor | CNR2, CNR1, OPRL1 | ALDH1A1 2533/4885MAPT 3944/4885TSHR 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.